Amgen says dazodalibep met Phase 3 Sjögren's endpoint
OASIZ 301 met its systemic disease measure, but Amgen did not disclose the treatment gap; a second Phase 3 study is due to finish this year.
Health & Science
Medical and Pharmaceutical
Medical and pharmaceutical developments, psychedelics, and the research and safety questions around them.
Page 3
Lantheus Holdings wins FDA approval for Bravnetsa before Curium vote
The adult GEP-NET radiopharmaceutical is therapeutically equivalent to Lutathera, but Lantheus has not announced its launch date or price.
Immunovant drops cutaneous lupus program after IMVT‑1402 trial miss
The 57-patient study missed its Week 12 skin disease endpoint, leaving five other autoimmune indications on Immunovant's development calendar.
Ionis Pharmaceuticals' Phase 3 kidney trial meets proteinuria endpoint
Sefaxersen beat placebo on a week-37 urine protein measure, but Roche and Ionis have not disclosed the size of the effect or safety rates.
GRAIL jumps 34% as FDA staff raise no major concerns on Galleri cancer test
The Molecular and Clinical Genetics Panel votes Wednesday on whether the multi-cancer blood test is safe, effective and worth its risks.
Longeveron slides 59% after-hours from stem cell therapy study failure
A recent 1-for-10 reverse stock split hasn't had much of an impact
bioAffinity Technologies jumps 63% on Hong Kong lung cancer screening patent
The firm now has 16 international patents for CyPath Lung
Bedfont expands Smokerlyzer breath monitoring devices into Colombia
The devices measure carbon monoxide in a person's exhaled breath and report the results in parts per million
BioNTech's lung cancer drug outperforms chemo in clinical study
Results were revealed at this year's World Conference on Lung Cancer in Seoul
Arm CEO's AI cancer cure claims come amid pushback over similar ideas
He believes efficacious drugs will be developed and tested at lightning speed
Arm CEO sees AI accelerating cancer diagnosis, research and treatment
AI could consequently discover cancer treatments that researchers would not otherwise find during their lifetimes
Radiation-free scan lights up elusive lung cancer in mice
Results of a study on this technique are intriguing but limited
University of Louisville gifted US$4.5M for lung health studies
The school has been continually strengthening its role in respiratory research
New treatments and detection technologies reshape lung cancer care
Lung cancer remains the leading cause of cancer death in the United States
Europe authorises Vara AI to clear low‑risk mammograms without human read
A world-first approval breaking new ground in the cancer screening field
Daraxonrasib shrinks tumours in one‑third of lung cancer patients
Non-small-cell lung cancer accounts for most lung cancer diagnoses
Ultragenyx plunges after-hours from rare disease drug trial failure
Angelman syndrome is a rare genetic nervous system disorder causing severe developmental delay
bioAffinity jumps 45% from lung cancer phlegm test expansion
It is the only commercially available test of its kind
AI flags heart disease from routine ECG test within seconds
Artificial intelligence is making it easier to determine who needs a heart ultrasound most
Canadian government invests C$35M in expansion of Kardium's Vancouver facility
Kardium makes an advanced heart disorder treatment device
Revolution's newly approved drug doubles pancreatic cancer survival time
A 30-day course of Rasonque costs US$39,800
Propanc Biopharma skyrockets from pancreatic cancer drug breakthrough
Stock ascended by more than 150%
Galvanize Therapeutics finds signs Aliya PEF may activate immune response in lung cancer
The findings could help researchers understand whether Aliya treatments can complement existing cancer immunotherapies
Korean medtech operator Rayence launches portable 'Anywhere' X‑ray
Rayence's latest and greatest mobile devices feature a proprietary new de-noising feature
Artificial heart maker Picard soars from 39% revenue spike, narrowed net loss
SynCardia's Total Artificial Heart serves as a temporary solution while patients wait for donors
Young Muay Thai fighter's lung cancer death raises screening eligibility concerns
Many heavy smokers live into their senior years while others are taken far too young
Craif raises US$33M to get its urine cancer test into American clinics
Milestone follows the firm opening a California lab in April
Scribe Therapeutics develops one‑time cholesterol treatment without permanent gene editing
Scribe instead wants one treatment to keep PCSK9 switched down for an extended period
Moderna ascends more than 175% from cancer vaccine breakthrough
It marks the first successful Phase 3 trial for an mRNA-based cancer therapy
Research shines light on efficacy of 'Inflammacheck' lung cancer breath test
Small study yielded high accuracy, though larger-scale validation is still needed
New USD$60 blood test detects lung cancer using DNA chemical fingerprints
The team extracts cell-free DNA from a blood sample and chemically processes selected sections
Surgical robotics leader Intuitive sets up shop in Penang, Malaysia
Medtech firm will invest nearly half a billion over 5 years
USC researchers use quantum AI to improve cancer imaging
Doctors regularly use magnetic resonance imaging, computed tomography and ultrasound scans to diagnose diseases and plan treatments
Freenome gets FDA breakthrough designation for 'SimpleScreen' lung cancer blood test
Achievement builds on firm securing agency's approval for a colorectal cancer test variation
FDA panel to review GRAIL's Galleri multi-cancer blood test in September
The application contains results from more than 70,000 participants enrolled in the intervention arm of the NHS-Galleri trial
Sionna shares plummet after cystic fibrosis clinical trial failure
The 92% plunge has been beneficial for competitor Vertex Pharma
Manitoba Lung Association and BioMark use blood biopsy to tackle radon threat
They are organising a feasibility study assessing the efficacy of BioMark's blood test on those exposed to the gas
Lung cancer screening awareness remains low despite advances in early detection
The 2026 Lung Health Barometer found only 33 per cent of adults knew low-dose CT screening is available for high-risk people
Amplia signs Eli Lilly collaboration for Phase 1b/2b lung cancer trial
The companies have already prepared an advanced draft of the trial protocol
Median Technologies partners with Canon Medical to achieve lung cancer screening goals
Their collaboration seeks to expedite deployment of Median's AI-powered nodule detection system